

DATE 30/05/23 REF. NUM. 76886

## Notified Body Statement Letter for audit surveillance of SIDAPHARM P.C., "SIDAPHARM"

To whom it may concern,

Confirmation of the status of an appropriate surveillance in the framework of Regulation EU 2023/607 of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This letter confirms that, **EKAPTY**, a Notified Body (NB) designated against Medical Devices Directive (EU) 93/42/EEC (MDD) and identified by the number **0653** on NANDO, has provided a surveillance audit on 24/05/2023 for the extension of the validity of the certificate numbered 3050201023M issued in accordance with Directive 93/42/EEC. Following the successful completion of the audit, the validity of the above certificate extends to 26/05/2024.

During the transitional period devices of the aforementioned certificate taking under notification the complementary confirmation letter (protocol number 10070/30/05/23) can lawfully be placed on the market by the condition that they are subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607).

On behalf of tified Body,

> **HATIONAL EVALUATION CENTER** OF QUALITY AND TECHNOLOGY IN HEALTH SA. "EKAPTY" 10 STADIOU STR & 4 OMIROU STR, 105 64 ATHENS ATTIKI T: +302132026200, F: +302109615464

VAT: 090301769

Pikrou-Moraitaki Eleftheria

President and Managing Director of EKAPTY S.A.